BPC-157 vs KPV
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It has been extensively studied in animal models for tissue repair, gastroprotection, and tendon/ligament/muscle healing. Important: essentially all efficacy data are preclinical (rodent), there are no completed published human efficacy trials, and it is prohibited in sport by WADA.
Full profileKPV
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.
Full profile| BPC-157 | KPV | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Body Protection Compound 157, PL 14736, Pentadecapeptide BPC 157 | Lys-Pro-Val, Alpha-MSH C-terminal tripeptide |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 200mcg–1000mcg mcg, once or twice daily | 250mcg–1000mcg mcg, Once or twice daily |
| Administration | Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols) | Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal |
| Key side effects | Nausea (rare, typically at higher doses), Dizziness / lightheadedness shortly after injection (uncommon, anecdotal), Injection site redness or irritation, Human safety profile is not established — no controlled human trials | Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH) |
| Cited sources | 6 references | 3 references |
Key differences
- Evidence level differs: BPC-157 is preclinical only, while KPV is research-stage.
- Administration: BPC-157 — Subcutaneous injection (most common), Intramuscular injection, Oral (reduced bioavailability — used for gut-specific protocols); KPV — Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal.
- Frequency: BPC-157 is typically once or twice daily; KPV is Once or twice daily.
- Research depth: this profile cites 6 sources for BPC-157 vs 3 for KPV.
How each works
BPC-157
Preclinical rodent and in-vitro studies — predominantly from the Sikiric group in Zagreb, with mechanistic angiogenesis work from Pang's group in Taiwan — report accelerated healing of tendon, ligament, muscle, and gut tissue. Proposed mechanisms include modulation of the nitric oxide (NO) system, promotion of angiogenesis via the VEGFR2–Akt–eNOS pathway, upregulation of growth factor signaling, and effects along the gut–brain axis. Despite a large and internally consistent animal literature, BPC-157 has no completed human clinical efficacy trials and is an unapproved drug.
KPV
KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.